The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): Phase I results.
Gerald Steven Falchook
Research Funding - Millennium
Barbara Ann Goff
Honoraria - Lilly
Razelle Kurzrock
Research Funding - Millennium
Heidi J. Gray
No relevant relationships to disclose
Lainie P. Martin
No relevant relationships to disclose
Robert L. Coleman
No relevant relationships to disclose
Hua Liu
Employment or Leadership Position - Millennium
Xiaofei Zhou
Employment or Leadership Position - Millennium
Ely Benaim
Employment or Leadership Position - Millennium
Russell Schilder
Honoraria - Millennium